Viaderma Stock Beta
| VDRM Stock | USD 0.01 0.00 0.00% |
Viaderma fundamentals help investors to digest information that contributes to Viaderma's financial success or failures. It also enables traders to predict the movement of Viaderma Pink Sheet. The fundamental analysis module provides a way to measure Viaderma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viaderma pink sheet.
Viaderma |
Viaderma Company Beta Analysis
Viaderma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Viaderma Beta | -0.42 |
Most of Viaderma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viaderma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Viaderma has a Beta of -0.4212. This is 148.98% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The beta for all United States stocks is 180.8% higher than that of the company.
Viaderma Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viaderma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Viaderma could also be used in its relative valuation, which is a method of valuing Viaderma by comparing valuation metrics of similar companies.Viaderma is currently under evaluation in beta category among its peers.
As returns on the market increase, returns on owning Viaderma are expected to decrease at a much lower rate. During the bear market, Viaderma is likely to outperform the market.
Viaderma Fundamentals
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) | |||
| Net Income | (1.52 M) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Current Ratio | 0.29 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Beta | -0.42 | |||
| Market Capitalization | 82.27 K | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Working Capital | (445 K) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
| Z Score | -28.3 | |||
| Net Asset | 426.56 K |
About Viaderma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viaderma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viaderma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viaderma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.